The development and use of oral anticancer agents (OAAs) continue to grow, and supporting individuals on OAAs is now a priority as they find themselves taking these drugs at home with little professional guidance. This mapping review provides an overview of the current evidence concerning OAA-supportive adherence interventions, identifying potential gaps, and making recommendations to guide future work. Four large databases and the grey literature were searched for publications from 2010 to 2022. Quantitative, qualitative, mixed-method, theses/dissertations, reports, and abstracts were included, whereas protocols and reviews were excluded. Duplicates were removed, and the remaining publications were screened by title and abstract. Full-text publications were assessed and those meeting the inclusion criteria were retained. Data extracted included the year of publication, theoretical underpinnings, study design, targeted patients, sample size, intervention type, and primary outcome(s). 3175 publications were screened, with 435 fully read. Of these, 314 were excluded with 120 retained. Of the 120 publications, 39.2% ( = 47) were observational studies, 38.3% ( = 46) were quasi-experimental, and 16.7% ( = 20) were experimental. Only 17.5% ( = 21) were theory-based. Despite the known efficacy of multi-modal interventions, 63.7% ( = 76) contained one or two modalities, 33.3% ( = 40) included 3, and 3.3% ( = 4) contained four types of modalities. Medication adherence was measured primarily through self-report ( = 31) or chart review/pharmacy refills ( = 28). Given the importance of patient tailored interventions, future work should test whether having four intervention modalities (behavioral, educational, medical, and technological) guided by theory can optimize OAA-related outcomes.